Skip to main content

Novavax announces very successful bird flu vaccination results


WASHINGTON The Rockville, Md.-based biotech Novavax announced Tuesday that trials of its bird flu vaccine resulted in 94 percent of test subjects producing antibodies to the deadly H5N1 strain.

Unlike other flu vaccines, which are grown using viruses in eggs, the Novavax vaccine uses particles similar in structure to the virus but unable to replicate.

The H5N1 strain has been linked to 110 deaths since 2005. Many experts fear that the strain, spread through direct contact between people and birds, could mutate into an airborne strain and lead to a pandemic.

This ad will auto-close in 10 seconds